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Pathogenic bacterial strains emerge largely due to
transfer of virulence and antimicrobial resistance
genes between bacteria, a process known as hori-
zontal gene transfer (HGT).Clustered, regularly inter-
spaced, short palindromic repeat (CRISPR) loci of
bacteria and archaea encode a sequence-specific
defense mechanism against bacteriophages and
constitute a programmable barrier to HGT. However,
the impact of CRISPRs on the emergence of viru-
lence is unknown. We programmed the human
pathogen Streptococcus pneumoniae with CRISPR
sequences that target capsule genes, an essential
pneumococcal virulence factor, and show that
CRISPR interference can prevent transformation of
nonencapsulated, avirulent pneumococci into cap-
sulated, virulent strains during infection in mice.
Further, at low frequencies bacteria can lose CRISPR
function, acquire capsule genes, and mount a suc-
cessful infection. These results demonstrate that
CRISPR interference can prevent the emergence of
virulence in vivo and that strong selective pressure
for virulence or antibiotic resistance can lead to
CRISPR loss in bacterial pathogens.
INTRODUCTION
CRISPR loci, and their associated cas (CRISPR associated)
genes, encode a sequence-specific defensemechanism against
bacteriophage infection and plasmid conjugation known as
CRISPR interference (Deveau et al., 2010; Marraffini and Son-
theimer, 2010; Terns and Terns, 2011). CRISPR loci consist of
arrays of short repetitive sequences (approximately 40 bp long)
that are separated by equally short ‘‘spacer’’ sequences, many
of them derived from mobile genetic elements such as bacterio-
phages and plasmids. At the molecular level, CRISPR interfer-
ence can be divided into three phases. In the adaptation phase,
new repeat-spacer units are incorporated (Barrangou et al.,
2007) to reprogram CRISPR interference against new invasive
nucleic acids, allowing the cell to adapt rapidly to the invadersCell Hospresent in the environment. During the crRNA biogenesis
phase, repeat/spacer arrays are transcribed as a long precursor
that is cleaved within repeat sequences and processed into
small CRISPR RNAs (crRNAs) by Cas endoribonucleases
(Brouns et al., 2008; Carte et al., 2008; Deltcheva et al., 2011;
Hatoum-Aslan et al., 2011; Haurwitz et al., 2010). CrRNAs
retain spacer sequences that specify the targets of CRISPR
interference. In the targeting phase crRNAs are used as anti-
sense guides in Cas/crRNA ribonucleoprotein complexes
that cleave the nucleic acids of mobile genetic elements
carrying a cognate sequence in their genomes, known as the
protospacer (Garneau et al., 2010; Hale et al., 2009; Marraffini
and Sontheimer, 2008). In addition to spacer-target complemen-
tarity, the presence of a conserved short tri- or tetranucleotide
sequence, known as the protospacer adjacent motif (PAM),
is required for efficient CRISPR interference (Deveau et al.,
2008). It has been demonstrated that CRISPR can prevent
bacteriophage infection (Barrangou et al., 2007) and plasmid
conjugation (Marraffini and Sontheimer, 2008), two routes of
HGT, and also the artificial transformation of target plasmids
into electrocompetent cells (Marraffini and Sontheimer, 2008).
Natural transformation (Dubnau, 1999) and electroporation
(Weaver, 1995) differ primarily in the mechanism by which exog-
enous DNA enters the cell. Whether CRISPR interference can
affect the transformation of naturally competent cells remains
to be demonstrated.
The lateral transfer of genes between related or unrelated
species via bacteriophage transduction, plasmid conjugation,
and DNA transformation is fundamental for prokaryotic evolu-
tion. In particular, the transfer of virulence and antimicrobial
resistance genes is largely the cause for the emergence of en-
hanced pathogenic strains (Furuya and Lowy, 2006). Sequence
analysis of pathogenic enterococci revealed a correlation
between the absence of CRISPR/Cas loci and the accumulation
of antibiotic resistance genes, suggesting that CRISPR loci
present a barrier to the transfer of traits under selective pressure
during infection (Palmer and Gilmore, 2010). This result
shows that CRISPR immunity can play an important role in the
evolution of bacterial pathogens, however the impact of
CRISPR/Cas loci in the emergence of virulence is not known.
Here we decided to test the activity of CRISPR/Cas loci against
the emergence of virulence in the human pathogen Strepto-
coccus pneumoniae. The pneumococcus displays a unique
ability to incorporate new genetic material via HGT, particularlyt & Microbe 12, 177–186, August 16, 2012 ª2012 Elsevier Inc. 177
Figure 1. CRISPR Interference Prevents Transformation of Naturally
Competent Pneumococci
(A) The IS1167 element of S. pneumoniae R6 was replaced by the CRISPR01
locus of S. pyogenes SF370 to generate the S. pneumoniae crR6 strain. The
aphA-3 gene encodes kanamycin resistance and was used for the selection of
recombinants.
(B) The first spacer (spc1) of S. pneumoniae crR6 matches the S. pyogenes
prophages f8232.5 (perfect match) and f370.1 (containing mismatches in the
target and flanking sequences, in white letters, that abrogate CRISPR inter-
ference).
(C) Donor strains were generated by insertion of the target (f8232.5) or control
(f370.1) sequences into the srtA locus of S. pneumoniae R6 cells, in both
directions (d, direct; i, inverted). A chloramphenicol resistance cassette (cat)
was also inserted for the selection of transformants.
(D) Primer extension analysis on total RNA of S. pneumoniae R6 and crR6
strains using primer L471, which anneals to the repeat sequences of the
CRISPR array. The expected product (42 nt) was detected in the crR6 strain
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(Avery et al., 1944; Griffith, 1928). In response to the immune
system attack pneumococci can change their surface polysac-
charide capsule through the acquisition of new capsule-encod-
ing genes, avoid capsule-specific antibodies, and establish
a successful infection (Griffith, 1928). This phenomenon, known
as capsule-switching, is a fundamental mechanism for the rapid
evolution of S. pneumoniae (Croucher et al., 2011). None of the
available pneumococcal genomes harbor CRISPR loci (Grissa
et al., 2007; Makarova et al., 2011a, 2011b), therefore we intro-
duced CRISPR sequences from related streptococci into
S. pneumoniae and showed that CRISPR interference can
prevent DNA transformation of pneumococci. We also reprog-
rammed CRISPR sequences to target capsule genes and per-
formed the classic experiments by Avery (Avery et al., 1944)
and Griffith (Griffith, 1928) to demonstrate that CRISPR activity
can abrogate capsule-switching, both in vitro and in mice.
However, we found that at low frequencies bacteria can lose
CRISPR function, acquire the capsule genes, and mount
a successful infection. These results demonstrate that CRISPR
interference can play an important role in the emergence of
new pathogenic strains and that strong selective pressure for
virulence or antibiotic resistance may lead to CRISPR loss
in S. pneumoniae, enterococci, and perhaps other bacterial
pathogens.
RESULTS
CRISPR Interference Can Prevent DNA Transformation
of Naturally Competent Pneumococci
We decided to determine whether CRISPR interference can
prevent DNA transformation of naturally competent pneumo-
cocci. Because none of the sequenced pneumococcal genomes
carry CRISPR/Cas loci, we integrated the CRISPR01 locus of
Streptococcus pyogenes SF370 (Ferretti et al., 2001) into
nonencapsulated S. pneumoniae R6 (Hoskins et al., 2001) cells
using the pCEP plasmid (Guiral et al., 2006), generating the
S. pneumoniae crR6 strain (Figure 1A). This CRISPR/Cas system
contains a tracrRNA, four cas genes, and one array of seven
repeats and six spacers, five of them matching different
S. pyogenes prophages (Deltcheva et al., 2011). To test CRISPR
interference against DNA transformation, we used chromosomal
DNA of S. pneumoniae donor strains carrying an engineered
spacer 1 (spc1) target. These strains were generated by fusing
a chloramphenicol resistance cassette to a 400 bp sequence
of S. pyogenes prophages f8232.5 or f370.1 containing the
30 bp spc1 target. f8232.5 has a perfect match with spc1; in
contrast, f370.1 displays several mismatches in the target as
well as flanking regions (Figure 1B) that would prevent CRISPR
interference and serves as a control for our experiment.but not in the R6 control. As a loading control, primer extension of the 5S rRNA
is shown.
(E) S. pneumoniae R6 or crR6 competent cells were incubated with 10 ng DNA
purified from each donor strain, and chloramphenicol-resistant transformants
were enumerated. The average of at least three independent measures of the
transformation efficiency (determined as cfu/mg DNA, Table S1) is reported,
and error bars indicate 1 SD. The dotted line indicates the limit of detection of
the assay.
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Figure 2. Acquisition of Antibiotic Resistance Genes Targeted by
CRISPR Interference Results in the Loss of CRISPR Function
(A) Transformation experiments performed with different amounts of target—
R68232.5(d)—or control—R6370.1(d)—DNA showed a low number of chloram-
phenicol-resistant transformants that ‘‘escaped’’ CRISPR interference at high
concentrations of donor DNA. The average of at least three independent
measures of the transformation efficiency (determined as cfu/mg DNA, Table
S2) is reported and error bars indicate 1 SD.
(B) Eight escapers were subjected to PCR analysis to determine the integrity of
the target integration site (L422/L426 and B73/L426), the CRISPR/Cas locus
(L414/L415), and the CRISPR array (L400/L460).
(C) Agarose gel electrophoresis of PCR products using escaper DNA as
template. L422/L426 and B73/L426 PCR products showed that the integration
site is intact for all escapers except #1 and #5. These escapers contain
deletions and insertions that most likely result from illegitimate recombination
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Cell HosConstructs were inserted into the nonessential srtA locus of R6
strain (Kharat and Tomasz, 2003) in both directions—direct (d)
or inverted (i) insertion, to test interference against both DNA
strands—to create two S. pneumoniae strains carrying CRISPR
interference targets (R6f8232.5-d and R6f8232.5-i) and two with
control sequences (R6f370.1-d and R6f370.1-i) (Figure 1C). Heter-
ologous expression of crRNAs in S. pneumoniae crR6 cells was
confirmed by primer extension analysis (Figure 1D). Genomic
DNA from donor strains was purified and incubated with com-
petent S. pneumoniae crR6 cells (Figure 1E). No chloramphen-
icol-resistant transformants were detected when we used target
DNA but many colonies were observed using control DNA.
Transformation of the non-CRISPR strain S. pneumoniae R6
produced many colonies with both target and control DNA (all
transformation efficiencies obtained in this work are reported
in Tables S1 and S2). These results indicate that CRISPR in-
terference can prevent transformation of naturally competent
bacteria. Combined with previous work (Barrangou et al.,
2007; Marraffini and Sontheimer, 2008), our observation estab-
lishes that CRISPR/Cas systems constitute a barrier against all
routes of HGT.
Active CRISPR/Cas Loci and Their Targets Cannot
Coexist in the Same Cell
Interestingly, at higher concentrations of donor DNA we
obtained a low number of chloramphenicol-resistant R6f8232.5-d
transformants that escaped CRISPR interference (Figure 2A).
PCR and sequencing analyses of eight of these escapers
revealed that two were the result of illegitimate recombination
of the cat gene that eliminated the target sequence (Figures 2B
and 2C, confirmed by sequencing analysis of the PCR products)
and one contains a mutation in the PAM of the target sequence
(Figure S1). The remaining escapers contained inactivated
CRISPR loci. Two escapers lacked spc1, most likely as a result
of recombination between repeats, and the rest lacked the full
CRISPR locus (Figures 2B and 2C). PCR analysis showed that
these escapers carry the donor strain R6f8232.5-d locus where
the CRISPR sequences were originally integrated, suggesting
that they originate from a double recombination event, one that
removes the CRISPR sequences and another that integrates
the cat gene and the CRISPR targets. These genetic alterations
were corroborated in functional analysis in which the DNA of
escapers was used to transform R6370.1(d), R68232.5(d), R6, or
crR6 competent cells (Table 1).
These and other results (Edgar and Qimron, 2010; Gudbergs-
dottir et al., 2011) suggest that CRISPR/Cas systems and their
targets cannot coexist in the same cell. To unequivocallyof the cat gene. L414/L415 PCR products showed that escapers #1, 2, 3, 5,
and 8 harbor a full CRISPR/Cas locus (13.1 kb). In contrast, escapers #4, 6,
and 7 showed a smaller product, suggesting that the IS1167 locus of strain
R68232.5(d) was recombined to replace the CRISPR/Cas locus. Finally, L400/
L460 PCR showed that escaper #8 lost spc1, and #2 lost both spc1 and spc2,
presumably through recombination between repeat sequences. Escaper #3
contained a mutated PAM sequence (see Figure S1).
(D) Competent cells containing the target (R68232.5(d) and R68232.5(i)) or a control
sequence (R6370.1(d) and R6370.1(i)) in both directions, were incubated with
30 ng of genomic DNA purified from S. pneumoniae crR6Strp cells. The average
of at least three independent measures of the transformation efficiency
(determined as cfu/mg DNA, Table S1) is reported and error bars indicate 1 s.d.
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Table 1. Functional Test of Escapers
Escaper Recipient Strain Selectiona Transformation Functional CRISPR Functional Target Genotypeb
1 R6370.1(d) Kanamycin + Yes No Illegitimate recombination
of cat gene with
target loss
R68232.5(d) Kanamycin -
R6 Choramphenicol +
crR6 Choramphenicol +
2 R6370.1(d) Kanamycin + No Yes spc1 deletion
R68232.5(d) Kanamycin +
R6 Choramphenicol +
crR6 Choramphenicol -
3 R6370.1(d) Kanamycin + Yes No PAM mutation
R68232.5(d) Kanamycin -
R6 Choramphenicol +
crR6 Choramphenicol +
4 R6370.1(d) Kanamycin - No Yes CRISPR/Cas deletion
R68232.5(d) Kanamycin -
R6 Choramphenicol +
crR6 Choramphenicol -
5 R6370.1(d) Kanamycin + Yes No Illegitimate recombination
of cat gene with
target loss
R68232.5(d) Kanamycin -
R6 Choramphenicol +
crR6 Choramphenicol +
6 R6370.1(d) Kanamycin - No Yes CRISPR/Cas deletion
R68232.5(d) Kanamycin -
R6 Choramphenicol +
crR6 Choramphenicol -
7 R6370.1(d) Kanamycin - No Yes CRISPR/Cas deletion
R68232.5(d) Kanamycin -
R6 Choramphenicol +
crR6 Choramphenicol -
8 R6370.1(d) Kanamycin + No Yes spc1 deletion
R68232.5(d) Kanamycin +
R6 Choramphenicol +
crR6 Choramphenicol -
aPresence of kanamycin-resistant transformants indicates recombination of the CRISPR/Cas locus. Recombination into R6370.1(d) cells, but not into
R68232.5(d), indicates the presence of an active CRISPR/Cas locus in the escaper; whereas recombination into both indicates the presence of an inac-
tive CRISPR/Cas locus in the escaper. Absence of transformants in both strains indicates complete loss of the CRISPR/Cas locus in the escaper. Pres-
ence of chloramphenicol-resistant transformants indicates recombination of the cat gene. Recombination into R6 cells but not into crR6 indicates the
presence of an intact target adjacent to the cat gene in the escaper, whereas recombination into both indicates the presence of a defective target in the
escaper.
bThe genotype was deduced after analysis of the functional tests reported in this table and the PCR and sequencing experiments shown in Figures 2
and S1.
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switched the donor and recipient strains of our assay; i.e., we
used S. pneumoniae crR6SrtpR DNA to transform R6f8232.5 or
R6f370.1 competent cells. The crR6Strp strain contains the
aphA-3 gene (providing for kanamycin resistance) linked to the
CRISPR locus as well as an unlinked rpsL allele that confers
streptomycin resistance (Tomasz, 1970), and which selection
serves as a transformation control. After transformation, no
kanamycin-resistant transformants were observed when cells
contained the spc1 CRISPR target (R68232.5(d) and R68232.5(i)
strains, Figure 2D). In contrast, many kanamycin-resistant colo-180 Cell Host & Microbe 12, 177–186, August 16, 2012 ª2012 Elsevinies can be obtained in the absence of a target (R6370.1(d) and
R6370.1(i) strains). As a control for competence, streptomycin-
resistant transformants were also enumerated, showing that all
cells used are equally competent. It should be noted that the
difference in transformation efficiency between kanamycin-
and streptomycin-resistant transformants is likely due to the
disparity in the recombination event that is required to introduce
each antibiotic resistance gene; a single-nucleotide mutation in
the rpsL gene is needed to obtain streptomycin resistance,
whereas more than 10 kb need to be integrated into the chromo-
some to acquire the kanamycin resistance gene (recombinationer Inc.
Figure 3. CRISPR Interference Prevents Capsule-Switching In Vitro
(A) The CRISPR locus of S. pneumoniae crR6 cells was modified by the
introduction of a spacer (spcC) matching a region of the cap3C gene of the
type 3-capsule S. pneumoniae SV36 strain to generate the S. pneumoniae
crR6cap3C strain.
(B) S. pneumoniae R6, crR6 and crR6cap3C competent cells were transformed
with SV36 (or R6Strp control) genomic DNA in the presence of antiserum to
select against nonencapsulated pneumococci. Encapsulated or strepto-
mycin-resistant transformants were enumerated. The average of at least three
independent measures of the transformation efficiency (determined as cfu/mg
DNA) is reported and error bars indicate 1 SD (see Table S1).
(C) Enumeration of encapsulated and nonencapsulated colonies after trans-
formation of the S. pneumoniaeR6, crR6 and crR6cap3C strains. The average of
at least three independent measures of the cfu/ml count is reported and error
bars indicate 1 SD. (see Table S1).
(D) Colony morphology of nonencapsulated cells and encapsulated trans-
formants. Supernatants (S/N) of transformed R6 and crR6 cells contain only
encapsulated colonies. In contrast, no encapsulated colonies (and sporadic
nonencapsulated colonies) are detected in the S/N of transformation experi-
ments with the crR6cap3C strain. After vortexing and plating the transformation
reaction (Total), a mix of encapsulated and nonencapsulated colonies can be
detected in tubes containing R6 and crR6 cells, whereas only nonencapsu-
lated crR6cap3C colonies are obtained (see Figure S2 for a detailed protocol).
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Cell Hosof the whole CRISPR/Cas sequences is necessary too). This
indicates that the transfer of a full CRISPR/Cas system
carrying a chromosome-targeting spacer can produce the
death of the recipient cell and presumably could be used to
develop technologies for the sequence-specific killing of
bacteria. More importantly, these data demonstrate that there
is a mutually exclusive relationship between CRISPR/Cas sys-
tems and their targets. Therefore CRISPR loci and their
targets cannot coexist in the same cell, and in a situation where
the target DNA confers a strong selective advantage, in our
experiments a target tightly linked to a gene providing antibi-
otic resistance, bacteria survivors acquired the selected gene
either after loss of CRISPR activity or mutation of the target
sequence.
CRISPR Interference Prevents Pneumococcal
Capsule-Switching In Vitro
Given the fundamental role of capsule-switching during pneu-
mococcal pathogenesis, as well as the availability of classic
assays to measure this phenomenon in vitro (Avery et al.,
1944) and in vivo (Griffith, 1928), we decided to test CRISPR
interference against capsular transformation. To achieve this,
we programmed the CRISPR locus of S. pneumoniae crR6 cells
against the cap genes responsible for capsule biosynthesis. We
introduced a spacer matching a 30 bp sequence in the cap3C
gene (Dillard et al., 1995) of the type 3 capsule strain SV36 (Nesin
et al., 1998), creating the S. pneumoniae crR6cap3C strain (Fig-
ure 3A). Genetic manipulation of the CRISPR array to engineer
this new spacer resulted in the replacement of the kanamycin
resistance gene by a chloramphenicol resistance marker (Fig-
ure S2). Strains R6, crR6, and crR6cap3C were tested for their
ability to acquire the type 3 capsule genes of strain SV36 in an
experiment designed by Avery and coworkers to demonstrate
that DNA is the molecule that carries the genetic information of
the cell (Avery et al., 1944). In this assay, nonencapsulated
competent bacteria are incubated with DNA purified from
encapsulated cells in the presence of antiserum against nonen-
capsulated cells. The antiserum prevents the growth of nonen-
capsulated cells and only transformed cells expressing the
type 3 polysaccharide capsule grow in the supernatant (Fig-
ure S2). While R6 and crR6 cells were able to be transformed
to become encapsulated, crR6cap3C cells remained nonencap-
sulated (Figure 3B). As a control for competence, all cells were
transformed with an rpsL allele that confers streptomycin
resistance. Plating of the total cell content also revealed a mix
of nonencapsulated and encapsulated colonies of the R6 and
crR6 strains, but only nonencapsulated crR6cap3C colonies
(Figures 3C and 3D). This experiment reveals that CRISPR
interference can prevent capsule-switching of pneumococci
in vitro.
In all transformation assays, strains carrying a nontargeting
CRISPR were transformed as efficiently as the strain lacking
the CRISPR/Cas system (Figures 1E and 3B, crR6 versus R6
strains). This suggests that the ‘‘naive’’ CRISPR system used in
this study does not undergo adaptation against the selected trait
(i.e., spacer acquisition) at a frequency that we could detect. We
also employed a highly sensitive method to look for spacer
acquisition by PCR amplification, recently described by Qimron
and colleagues (Yosef et al., 2012), without success.t & Microbe 12, 177–186, August 16, 2012 ª2012 Elsevier Inc. 181
Figure 4. CRISPR Interference Prevents Capsule-Switching during
Pneumococcal Infection
(A) Mice (n=5) were injected with 107 cfu of live, nonencapsulated
S. pneumoniae crR6 or crR6cap3C cells mixed with 108 cfu of heat-killed,
encapsulated S. pneumoniae R6III cells. As controls, live crR6, R6III, and heat-
killed R6III cells were also injected. Animals were monitored for signs of
pneumococcal disease for 10 days and their survival plotted over time (day ‘‘0’’
is the day of injection).
(B) Mice (n=4) were injected intraperitoneally with 108 cfu of live, nonencap-
sulated S. pneumoniae crR6 or crR6cap3C-StrpR cells mixed with 108 cfu of heat-
killed, encapsulated S. pneumoniae R6III cells. Day ‘‘0’’ is the day of infection.
Animals were monitored for signs of pneumococcal disease for 10 days and
their survival plotted over time. All mice that were injected with strain crR6 and
one mouse of the four injected with strain crR6cap3C-StrpR became sick within
24 hr. Mice that succumbed to pneumococcal infection were dissected and
hearts resuspended in 1 ml of saline buffer. Resuspensions were streaked to
determine both capsule and antibiotic resistance phenotypes.
(C) Bacteria that were able to escape CRISPR interference against capsule
transformation in the mouse were all capsulated and chloramphenicol- and
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Pneumococci during Infection
The polysaccharide capsule of pneumococci prevents the
phagocytosis of this bacterium and therefore is an essential viru-
lence factor of pneumococcal disease (Avery and Dubos, 1931).
The requirement of a capsule for the establishment of a success-
ful infection allowed Griffith to detect capsular transformation
in vivo in the 1920s (Griffith, 1928). In this experiment, intraper-
itoneal injection of mice with a mix of live, nonencapsulated,
avirulent pneumococci and heat-killed, encapsulated, virulent
cells leads to the development of pneumococcal infection after
in vivo acquisition of capsule genes by the nonencapsulated
cells. To test whether CRISPR interference can prevent the
transfer of capsule genes during infection, we performed
Griffith’s experiment and coinjected mice with 107 live, nonen-
capsulated crR6 or crR6cap3C cells and 108 heat-killed R6III cells.
S. pneumoniae R6III strain is a type 3 encapsulated R6 deriva-
tive containing the capsule genes from SV36 that is equally path-
ogenic in the mouse model of infection (Kharat and Tomasz,
2003) and shares an isogenic background with crR6 or
crR6cap3C, thus facilitating recombination and transformation.
Cells lacking the capsule-specific spacer were able to acquire
the cap3 operon, produce capsule, and cause pneumococcal
disease in 4 out of 5 mice (Figure 4A). We believe that trans-
formation, which occurs at low frequency in the peritoneal cavity
(Griffith, 1928; Zhu and Lau, 2011), did not produce enough
encapsulated pneumococci to cause infection in the only
surviving mouse. In contrast, CRISPR interference prevented
the transfer of the cap3 genes to crR6cap3C cells, and mice
survived infection. When injected individually, neither crR6,
crR6cap3C, nor heat-killed R6III cells caused disease. These
results show that CRISPR interference can prevent HGT in vivo
in the context of a bacterial infection.
We predicted that, as we found in the in vitro transformation
experiments, CRISPR activity could be lost during infection
and lead to the rise of cells able to acquire the cap3 operon
and mount a successful infection. To test this possibility, we
repeated Griffith’s experiment with more cells in order to
increase the chances of obtaining such ‘‘escapers.’’ The exper-
iment was performed with a streptomycin-resistant variant of
crR6cap3C, crR6cap3C-StrepR. In this way, the resulting transform-
ants cannot be mistaken for virulent cells that escaped the
heat-killing procedure. Upon the injection of 108 crR6cap3C-StrepR
cells with 10
8
heat-killed R6III cells, 1 out of 4 mice died (Fig-
ure 4B). Bacteria recovered from blood were capsulated and
streptomycin- and chloramphenicol-resistant, indicating that
the transformants maintained the CRISPR locus. Upon
sequencing of the CRISPR locus, we detected a mutation that
introduced a premature stop codon in cas9 (Figure 4C), an
essential gene for the activity of this CRISPR/Cas system
(Deltcheva et al., 2011). Therefore, as is the case for antibiotic
selection, CRISPR targeting of virulence genes can select for
the loss of CRISPR function during infection, when the acquisi-
tion of those genes is under strong selective pressure.streptomycin-resistant. Sequence analysis of the CRISPR/Cas locus revealed
a T to A mutation (highlighted in yellow) in the cas9 gene that introduces a stop
codon in place of a leucine residue (L1236) in the Cas9 protein (1368 aa).
er Inc.
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The spacer content of a CRISPR array specifies the targets of
CRISPR interference. The great majority of spacer hits are map-
ped to bacteriophages and conjugative plasmids, but there are
also a small number of spacers that match chromosomal
sequences unrelated tomobile genetic elements present in other
species (Brodt et al., 2011). This indicates that the CRISPR/Cas
systems often come into contact with foreign chromosomal DNA
that is transferred through HGT, i.e., bacteriophage transduc-
tion, plasmid conjugation, or transformation. CRISPR interfer-
ence has been shown to prevent bacteriophage infection and
plasmid conjugation. Here we show that CRISPR interference
can also prevent natural transformation of S. pneumoniae,
establishing that CRISPR/Cas systems constitute a barrier
against all mechanisms of HGT. Since HGT is a fundamental
source of new genetic material in prokaryotes, CRISPR loci
play an important role in the maintenance of genome integrity
in addition to their function in antiviral immunity. Barriers against
HGT are highly valuable to the prokaryotic cell, as many horizon-
tally acquired genes are likely to cause deleterious effects in the
chromosome of the bacterial recipient (Thomas and Nielsen,
2005). However when CRISPR/Cas systems target DNA mole-
cules that confer a selective advantage to the host, these loci
may reduce the ability of the bacterium to evolve and adapt.
In bacterial pathogens HGT provides the mechanisms for the
spread of antimicrobial resistance and virulent traits (Furuya
and Lowy, 2006). A remarkable example of this is found in
S. pneumoniae. In this bacterium, DNA transformation provides
the genetic diversity required for the rapid adaptation to clinical
interventions such as the introduction of antibiotic therapy and
anti-capsule vaccines (Croucher et al., 2011). Here we used
the pneumococcus to test the activity of CRISPR/Cas loci
against the transfer of genes that commonly confer selective
advantage to pathogens: antibiotic resistance and virulence
genes. We found that, provided with appropriate sequence-
specific spacers, CRISPR interference can prevent the transfer
of these genes, not only in vitro, but also in vivo, in the context
of a pneumococcal infection. We determined that the inverse is
also true: the transfer of CRISPR/Cas systems into a recipient
cell containing a target leads to the death of the transformants.
These and other results (Edgar andQimron, 2010; Gudbergsdot-
tir et al., 2011) indicate that CRISPR loci and their targets cannot
coexist in the same cell.
What are the genetic consequences of this mutually exclusive
relationship? We answer this question by analyzing cells that
survived CRISPR interference. In vitro, using a target that is
tightly linked to an antibiotic resistance gene and selecting for
antibiotic-resistant cells, we observed that survivors frequently
contained deletions of the spacer targeting the transforming
DNA or a complete deletion of the CRISPR/Cas locus. To study
the effect of CRISPR interference against the horizontal transfer
of virulence genes in vivo, we engineered a spacer against
a capsule polysaccharide synthesis gene that is essential during
pneumococcal infection. In this experiment selection was pro-
vided by the mouse immune system, capable of killing non-
encapsulated but not encapsulated bacteria. Similarly to the
transformation of antibiotic resistance gene experiment, this
strong selection for encapsulated pneumococci during infectionCell Hosalso allowed us to detect the occasional rise of clones that were
able to acquire capsule genes due to the presence of a non-
sense mutation in an essential cas gene that inactivated the
CRISPR/Cas system. Therefore, when CRISPR/Cas systems
target molecules carrying genes that confer adaptive traits,
strains with deleted or incapacitated CRISPR/Cas loci are
selected. This could explain the correlation between the pres-
ence of antibiotic resistance genes and the lack of CRISPR loci
found in clinical strains of pathogenic enterococci (Palmer and
Gilmore, 2010). To our knowledge, spacers that target virulence
or antibiotic resistance genes have not yet been found in natural
isolates, but can be acquired from antibiotic-resistant plasmids
artificially introduced into the cell (Garneau et al., 2010). Although
the mechanism of new spacer acquisition is yet poorly under-
stood, it is clear that the CRISPR arrays can efficiently incorpo-
rate many different spacer sequences, even sequences present
in eukaryotic genomes (Brodt et al., 2011). Therefore it is likely
that CRISPR loci would occasionally gain spacers blocking the
transfer of resistance and/or virulence genes. In this context,
our results provide experimental support for a mechanism by
which enterococci, and perhaps other pathogens, could lose
CRISPR sequences.
The reason for the absence of CRISPR/Cas loci in all of the
available S. pneumoniae genomes is not known. CRISPR/Cas
systems are thought to be transferred by HGT (Godde and Bick-
erton, 2006); therefore the acquisition of CRISPR sequences
by pneumococci is a likely event, considering that many of
the species that inhabit the nasal flora, such as staphylococci,
corynebacteria, and other streptococci, contain CRISPR/Cas
systems (Grissa et al., 2007) that could be transferred to
S. pneumoniae. Moreover, different strains of Streptococcus
oralis and Streptococcus mitis, two species closely related to
S. pneumoniae, carry different types of CRISPR/Cas systems
(Grissa et al., 2007). One possibility for the absence of CRISPR
loci in pneumococci is that bacteriophage activity against this
bacterium is not sufficiently high to select for this antiviral
immune system. This seems unlikely since phages are ubiqui-
tous and many are known to infect S. pneumoniae (Garcia
et al., 1997). Alternatively, CRISPR/Cas loci could have a fitness
cost for this bacterium and be lost if acquired; however, in labo-
ratory media strains R6 and crR6 have similar growth rates (data
not shown). We do not know why pneumococci lack CRISPR
loci, but in light of our results and the importance of HGT for
pneumococci, it is possible that the barrier to gene transfer
imposed by CRISPR/Cas loci could prevent the selection of
these loci in S. pneumoniae. Similar considerations could be
applied to other bacteria as well. It is intriguing that, whereas
lethal bacteriophages are omnipresent, this highly valuable anti-
viral immune system is present in only 40% of the bacterial
genomes (Grissa et al., 2007; Makarova et al., 2011a, 2011b).
The presence of CRISPR loci in a given strain could thus be
the result of a trade-off between the ability to defend against
phages or other undesirable genetic elements and the ability to
adapt efficiently. Further evolutionary studies will need to be per-
formed to understand the impact of this barrier to HGT on the
evolvability of pathogens and of all prokaryotes in general.
S. pneumoniae strains exhibit an impressive variability of
capsular polysaccharide antigens, presenting over 90 serotypes.
The recent introduction of anti-capsule vaccines, particularly oft & Microbe 12, 177–186, August 16, 2012 ª2012 Elsevier Inc. 183
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disease, but also resulted in the rise of non-vaccine-serotype
pneumococci, such as the multidrug-resistant serotype 19A
(Croucher et al., 2011; Moore et al., 2008). This highlights the
importance of capsule-switching in pneumococcal disease.
Here we show that CRISPR/Cas systems can be effectively
introduced into S. pneumoniae and be reprogrammed to prevent
capsule-switching. We designed a spacer against a type 3
capsule synthesis gene, and the repertoire of anti-capsule
spacer could easily be expanded to cover many different
capsular types. This approach might be applied to the study
and control of the emergence of new capsular serotypes.
Finally our results suggest a possible use for CRISPR/Cas
systems to combat bacterial pathogens. In addition to demon-
strating that CRISPR interference works in vivo in the context
of a bacterial infection, we also show that the transfer of CRISPR
loci targeting a chromosomal region associated with antibiotic
resistance leads to the death of the recipient cell. These obser-
vations present the possibility of using mobile CRISPR systems
engineered to target antibiotic resistance and/or virulence genes
to specifically kill pathogens carrying these genes. A high rate of
transfer is fundamental for the success of this method. Currently
there are technologies that use both conjugative plasmids
(Filutowicz et al., 2008) and bacteriophage encapsidation (Fair-
head, 2009) to deliver toxin genes to (and thus kill) pathogenic
bacteria. We believe that the same technologies can be used
to deliver engineered CRISPR/Cas systems that would kill cells
containing target sequences such as antibiotic resistance genes
or virulence factors, a specificity that cannot be achieved with
other antimicrobials.
EXPERIMENTAL PROCEDURES
Strains and Culture Conditions
S. pneumoniae strains R6 (Hoskins et al., 2001), R6Strp (Tomasz, 1970), and
SV36 (Nesin et al., 1998) were provided by Alexander Tomasz. Liquid cultures
of S. pneumoniae were grown in THYE medium (30 g/l Todd-Hewitt agar, 5 g/l
yeast extract). Cells were plated on tryptic soy agar (TSA) supplemented with
5% defibrinated sheep blood. When appropriate, antibiotics were added as
follows: kanamycin (400 mg/ml), chloramphenicol (5 mg/ml), or streptomycin
(100 mg/ml).
S. pneumoniae Transformation
Competent cells were prepared as described by Martin et al. (Martin et al.,
1995). An overnight THYE culture was diluted to OD600 0.05 in M1 medium
(THYE with 0.2% BSA, 1 mM CaCl2, pH 7.1) and grown until OD600 0.15. Cells
were concentrated 10 times, supplemented with 10% glycerol, and frozen
at 80C for later use. Cells were gently thawed on ice, pelleted, and resus-
pended in M2 medium (M1 medium at pH 7.9) supplemented with 100 ng/ml
of competence-stimulating peptide CSP1 (Ha˚varstein et al., 1995). Cells
were incubated 20 min at 37C before the addition of 0.001 to 3 mg of genomic
DNA and then incubated 3 hr at 37C. Serial dilutions of cells were plated on
the appropriate medium to determine the cfu count.
Selection of Encapsulated Transformants
Antiserum against nonencapsulated pneumococci was recovered from
C57BL/6 mice after three biweekly intraperitoneal injections of 106
S. pneumoniae crR6 cells. Antiserum was heated 30 min at 60C to inactivate
nucleases and stored at 4C. After incubation in M2medium containing CSP1,
competent S. pneumoniae R6, crR6, or crR6cap3C cells were diluted 1:100 into
M2 medium supplemented with CSP1 (100 ng/ml) and 2% of antiserum (Fig-
ure S2B). This was followed by the addition of 1 mg of genomic DNA purified
from S. pneumoniae SV36 and overnight incubation at 37C. Encapsulated184 Cell Host & Microbe 12, 177–186, August 16, 2012 ª2012 Elsevitransformants grow normally in the medium, while nonencapsulated cells
are agglutinated by the antiserum at the bottom of the tube. After incubation,
serial dilutions of the supernatant were plated in TSA/blood plates without
antibiotics to enumerate encapsulated cfu. To count total cfu, cells were
vortexed prior to plating. As a control an aliquot of the competent cells was
transformed with 1 mg of genomic DNA purified from S. pneumoniae R6Strp.
Primer Extension Assays
Total RNA was extracted from exponentially growing cultures of
S. pneumoniae R6 and crR6 strains using TRIzol (Invitrogen) and following
the manufacturer’s instructions. Primer extensions were performed as
described previously (Hatoum-Aslan et al., 2011) using PAGE purified primers
L471 for the extension of CRISPR01 crRNAs and L472 for the extension of
S. pneumoniae R6 5S rRNA.
Infection of Mice with S. pneumonia
For infection experiments, S. pneumoniae crR6, crR6cap3C, and crR6 cap3C -Strp
strains were grown overnight in THYE at 37C, diluted into 10ml of fresh media
to an initial OD600 of 0.05, and incubated at 37
C until cultures reached an
OD600 of 0.2. Pneumococci were collected by centrifugation, washed, and
suspended in 500 ml of sterile saline buffer, containing a total of approximately
108 cfu. Encapsulated R6III cells were diluted into 50 ml of fresh media and
incubated until cultures reached an OD600 of 1.0. Pneumococci were
collected by centrifugation, washed, and suspended in 500 ml of sterile saline
buffer, containing a total of approximately 109 cfu. Resuspended cells were
incubated at 65C for 30 min. Bacterial suspensions were further diluted
with sterile saline to obtain an infectious dose of 107 crR6 or crR6cap3C cfu
or 108 heat-killed R6III cfu in 100 ml of inoculum. Due to their high pathogenicity,
live S. pneumoniae R6III cells were diluted to 103 cfu per 100 ml of inoculum.
Pneumococci were administered intraperitoneally into 6- to 8-week-old CD1
Swiss mice (Kharat and Tomasz, 2003). Five mice per experiment were used
for the injection of the following strains or combination of strains: live
S. pneumoniae R6III, crR6, or crR6cap3C cells; heat-killed S. pneumoniae R6III
cells; or a combination of live S. pneumoniae crR6 or crR6cap3C cells with
heat-killed S. pneumoniae R6III cells. Injection of a combination of live and
heat-killed cells was carried out by mixing bacteria immediately before
inoculation and maintaining the mix on ice to prevent transformation. Viable
pneumococci were enumerated by colony formation on TSA-blood plates to
quantify infectious doses and corroborate the absence of encapsulated trans-
formants in the mixed doses. Animals were monitored for 10 days and those
showing signs of disease were euthanized by CO2 asphyxiation. Hearts
were removed and resuspended in 1 ml of sterile saline buffer, and serial dilu-
tions were plated on TSA-blood to determine the presence of capsule. Further
corroboration of the genetic identity of the transformed S. pneumoniae crR6
bacteria was performed by streaking colonies on kanamycin-containing plates
and PCR analysis.
To obtain transformants that evade CRISPR interference during
infection, we increased the dose of live, nonencapulated cells (crR6 and
crR6 cap3C -Strp) to 108 cfu per injection. The inoculum of heat-killed R6III cells
wasmaintained at 108 cfu. Blood frommice that succumbed to pneumococcal
infection was streaked on kanamycin-, chloramphenicol-, or streptomycin-
containing plates, and the presence of genetic changes was determined by
PCR. Animal care and experimentation comply with the NIH guidelines and
were approved by the institutional Animal Care and Use Committee of The
Rockefeller University. The Rockefeller University is an AAALAC accredited
research institution that adheres to the rodent housing and care guidelines
provided in the Guide for the Care and Use of Laboratory Animals.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, two tables, and Supplemental References and can be found
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